The biotech scorecard for the 2nd quarter: 12 industry events to watch

APStockIntroducingSTAT’sBiotechQ2Scorecard,ouremoji-enabledmeansoftracking12make-or-breakeventsexpec EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad




hotspot

author：hotspot    Page View：4
Alexis Borisy
Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

advertisement

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In
Previous article： What is the Turing Test that determines if computers can think?
Next article： Apple is now the first public company to be valued at $3 trillion